COMMUNIQUÉS West-GlobeNewswire

-
Hairmax Partners with Truemed to Accept FSA/HSA Payments on FDA-Cleared Laser Hair Growth Devices
18/06/2025 -
BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates
18/06/2025 -
Eolo Pharma Publishes First-in-Human Study in Nature Metabolism on Novel Obesity Drug Activating Energy-Burning Pathway
18/06/2025 -
Bioxytran Secures a Source of GMP Quality Camel Hemoglobin
18/06/2025 -
Bay Area Lyme Foundation Announces New Executive Director Josh Wein
18/06/2025 -
Human Appeal announces summertime UK Comedy Tour
18/06/2025 -
Rarecells, Inc. Appoints Dr. Rita Shaknovich to Scientific Advisory Board
18/06/2025 -
Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates
18/06/2025 -
Sharps Technology Advances Shipment Under $50 Million SoloGard Supply Agreement and Begins Manufacturing Facility Upgrades
18/06/2025 -
Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing
18/06/2025 -
BPGbio Announces Presentation of Preliminary Clinical Data of Investigational BPM31510 for Primary CoQ10 Deficiency
18/06/2025 -
I-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025
18/06/2025 -
Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) Investor Webinar with Presentation and Audience Q&A
18/06/2025 -
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia
18/06/2025 -
Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)
18/06/2025 -
Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer
18/06/2025 -
Diagonal’s First-in-Class Clustering Antibody, DIAG723, Receives Orphan Drug Designation (ODD) from U.S. FDA and an ODD Positive Opinion from EMA for Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
18/06/2025 -
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
18/06/2025 -
Eccogene Announces First Patient Dosed in Phase 1b Trial of AZD5004/ECC5004, a Novel Oral GLP-1 Receptor Agonist, in China
18/06/2025
Pages